Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Cryopreservation Changes the Immune Effector Cell Composition of Peripheral Blood Stem Cell Grafts: An Analysis from the DKMS and NMDP Graft Composition Study

Blood (2023) 142 (Supplement 1): 1036.

https://doi.org/10.1182/blood-2023-179140

Published: 2023

Journal Articles

MAIT Cell Frequencies within PBSC Grafts Are Associated with Donor CMV Serostatus and Age: An Initial Analysis from the DKMS and NMDP Graft Composition Study

Blood (2023) 142 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2023-185153

Published: 2023

Journal Articles

Feasibility of Flow Cytometric Identification and Isolation of Pre-Platelets to Understand Its Function and Role in Cancer Metastasis

Taha Bat, MD, Eunice S. Wang, MD, Joanne Becker, MD, Orla Maguire, Hans Minderman, PhD, Jordan Cinquino, MD

Blood (2019) 134 (Supplement_1): 3688.

https://doi.org/10.1182/blood-2019-132241

Published: 2019

Journal Articles

Cyclosporine May Inhibit the Effect of Extra-Physiologic Oxygen Shock/Stress on Peripheral Blood Stem Cells

Amro Elshoury, MBBChir, Hans Minderman, PhD, Alexis Conway, PhD, Paul K. Wallace, MS, PhD, Charlie Mantel, Joseph Dennis Tario, PhD, Yeong Choi, Kieran O'Loughin, MS, Carlos Cedeno, PhD, Jenna Nichols, Kahteong Soh, MS, Philip L. McCarthy, MD, George Chen, MD

Blood (2018) 132 (Supplement 1): 3346.

https://doi.org/10.1182/blood-2018-99-119329

Published: 2018

Journal Articles

A Phase 1b Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-Azacitadine

Gautam Borthakur, MD, James M. Foran, MD, Eunice S. Wang, MD, Amol Rakkar, Hans Minderman, Jennifer Burns, Michael Andreeff, MD PhD, Raoul Tibes, MD PhD

Blood (2015) 126 (23): 93.

https://doi.org/10.1182/blood.V126.23.93.93

Published: 2015

Journal Articles

A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis

Gautam Borthakur, MD, James M. Foran, MD, Eunice S. Wang, MD, Amol Rakkar, Steven Hager, DO, Noelle V. Frey, MDMS, Michael Andreeff, MD PhD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Bing Z Carter, PhD, Hans Minderman, Lesley Russell, Raoul Tibes, MD PhD

Blood (2014) 124 (21): 3263.

https://doi.org/10.1182/blood.V124.21.3263.3263

Published: 2014

Journal Articles

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Noelle V. Frey, MDMS, Selina Luger, MD, James Mangan, MD PhD, Alexis Zebrowski, BA, Alison W. Loren, MDMS, Hans Minderman, John Baird, MD, David L Porter, MD, Elizabeth O. Hexner, MD, Anita J. Kumar, MDMS, Marlise R. Luskin, MD, Alexander E Perl, MD, Martin Carroll, MD

Blood (2014) 124 (21): 3758.

https://doi.org/10.1182/blood.V124.21.3758.3758

Published: 2014

Journal Articles

Knock-Down of Signal Transducer and Activator of Transcription 3 Enhances Acute Myeloid Leukemia-Derived Dendritic Cell Function.

Michael T. Brady, MS, Sheila N.J. Sait, PhD, Hans Minderman, PhD, Kelvin P. Lee, MD, Meir Wetzler, MD

Blood (2009) 114 (22): 1972.

https://doi.org/10.1182/blood.V114.22.1972.1972

Published: 2009

Journal Articles

Rapamycin Causes Reversible Cell Cycle Slowing, Rather Than Cell Cycle Arrest, in Myeloid and Lymphoid Cell Lines and in Acute Leukemia Cells

Amy Kimball, MD, PhD, Mehmet Burcu, BS, Kieran L O’Loughlin, MS, Laurie A. Ford, Hans Minderman, Maria Baer

Blood (2008) 112 (11): 5021.

https://doi.org/10.1182/blood.V112.11.5021.5021

Published: 2008

Journal Articles

Amonafide L-Malate Bypasses Multidrug Resistance Proteins in Secondary Acute Myeloid Leukemia.

Kieran L. O’Loughlin, BS, Hans Minderman, PhD, Laurie A. Ford, BS, Maria R. Baer, MD

Blood (2007) 110 (11): 2380.

https://doi.org/10.1182/blood.V110.11.2380.2380

Published: 2007

Journal Articles

The FLT3 Inhibitor PKC412 Interacts Synergistically with Both Daunorubicin and Cytarabine in Acute Myeloid Leukemia (AML) Cells by Heterogeneous Mechanisms.

Maria R. Baer, MD, Kareemah L. Sabur, Kieran L. O’Loughlin, BS, Petr Starostik, MD, Hans Minderman, PhD

Blood (2006) 108 (11): 1378.

https://doi.org/10.1182/blood.V108.11.1378.1378

Published: 2006

Journal Articles

The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.

Attaphol Pawarode, MD, Kieran L. O’Loughlin, MS, Nicholas W. Cuviello, William R. Greco, PhD, Laurie A. Ford, BS, Hans Minderman, PhD, Maria R. Baer, MD

Blood (2005) 106 (11): 1512.

https://doi.org/10.1182/blood.V106.11.1512.1512

Published: 2005

Journal Articles

Cyclosporine A Modulates the Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein, Breast Cancer Resistance Protein and Lung Resistance Protein.

Misbah Qadir, MD, Kieran L. O’Loughlin, MS, Nicole A. Williamson, BA, Hans Minderman, PhD, Maria R. Baer, MD

Blood (2004) 104 (11): 1180.

https://doi.org/10.1182/blood.V104.11.1180.1180

Published: 2004

Journal Articles

Acute Myeloid Leukemia Cells Are Resistant to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Mechanism Independent of Multidrug Resistance.

Stacy M. Fricke, BS, Hans Minderman, PhD, Kieran L. O’Loughlin, MS, Jinrong Cheng, MS, Elizabeth A. Repasky, PhD, Maria R. Baer, MD

Blood (2004) 104 (11): 4385.

https://doi.org/10.1182/blood.V104.11.4385.4385

Published: 2004

Journal Articles

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

Maria R. Baer, Stephen L. George, Richard K. Dodge, Kieran L. O'Loughlin, Hans Minderman, Michael A. Caligiuri, John Anastasi, Bayard L. Powell, Jonathan E. Kolitz, Charles A. Schiffer, Clara D. Bloomfield, Richard A. Larson

Blood (2002) 100 (4): 1224–1232.

https://doi.org/10.1182/blood.V100.4.1224.h81602001224_1224_1232

Published: 2002

Journal Articles

Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia

Udomsak Bunworasate, Hilal Arnouk, Hans Minderman, Kieran L. O'Loughlin, Sheila N. J. Sait, Maurice Barcos, Carleton C. Stewart, Maria R. Baer

Blood (2001) 98 (12): 3492–3494.

https://doi.org/10.1182/blood.V98.12.3492

Published: 2001

NARROW

Cryopreservation Changes the Immune Effector Cell Composition of Peripheral Blood Stem Cell Grafts: An Analysis from the DKMS and NMDP Graft Composition Study

MAIT Cell Frequencies within PBSC Grafts Are Associated with Donor CMV Serostatus and Age: An Initial Analysis from the DKMS and NMDP Graft Composition Study

Feasibility of Flow Cytometric Identification and Isolation of Pre-Platelets to Understand Its Function and Role in Cancer Metastasis

Cyclosporine May Inhibit the Effect of Extra-Physiologic Oxygen Shock/Stress on Peripheral Blood Stem Cells

A Phase 1b Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-Azacitadine

A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Knock-Down of Signal Transducer and Activator of Transcription 3 Enhances Acute Myeloid Leukemia-Derived Dendritic Cell Function.

Rapamycin Causes Reversible Cell Cycle Slowing, Rather Than Cell Cycle Arrest, in Myeloid and Lymphoid Cell Lines and in Acute Leukemia Cells

Amonafide L-Malate Bypasses Multidrug Resistance Proteins in Secondary Acute Myeloid Leukemia.

The FLT3 Inhibitor PKC412 Interacts Synergistically with Both Daunorubicin and Cytarabine in Acute Myeloid Leukemia (AML) Cells by Heterogeneous Mechanisms.

The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.

Cyclosporine A Modulates the Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein, Breast Cancer Resistance Protein and Lung Resistance Protein.

Acute Myeloid Leukemia Cells Are Resistant to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Mechanism Independent of Multidrug Resistance.

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only